KR20140040726A - PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법 - Google Patents
PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법 Download PDFInfo
- Publication number
- KR20140040726A KR20140040726A KR1020137031629A KR20137031629A KR20140040726A KR 20140040726 A KR20140040726 A KR 20140040726A KR 1020137031629 A KR1020137031629 A KR 1020137031629A KR 20137031629 A KR20137031629 A KR 20137031629A KR 20140040726 A KR20140040726 A KR 20140040726A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- optionally substituted
- formula
- heteroaryl
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480991P | 2011-04-29 | 2011-04-29 | |
| US61/480,991 | 2011-04-29 | ||
| US201161493998P | 2011-06-07 | 2011-06-07 | |
| US61/493,998 | 2011-06-07 | ||
| US201161566066P | 2011-12-02 | 2011-12-02 | |
| US61/566,066 | 2011-12-02 | ||
| PCT/US2012/035442 WO2012149308A1 (fr) | 2011-04-29 | 2012-04-27 | Méthode de traitement d'un lymphome à l'aide d'inhibiteurs de pyridopyrimidinone de pi3k/mtor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140040726A true KR20140040726A (ko) | 2014-04-03 |
Family
ID=46062758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137031629A KR20140040726A (ko) | 2011-04-29 | 2012-04-27 | PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140296265A1 (fr) |
| EP (1) | EP2701690A1 (fr) |
| JP (1) | JP2014513104A (fr) |
| KR (1) | KR20140040726A (fr) |
| CN (1) | CN103635183A (fr) |
| AR (1) | AR086209A1 (fr) |
| AU (1) | AU2012249500A1 (fr) |
| CA (1) | CA2834282A1 (fr) |
| EA (1) | EA201391606A1 (fr) |
| MX (1) | MX2013012486A (fr) |
| TW (1) | TW201311683A (fr) |
| UY (1) | UY34044A (fr) |
| WO (1) | WO2012149308A1 (fr) |
| ZA (1) | ZA201307952B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI642670B (zh) | 2010-09-14 | 2018-12-01 | 伊塞利克斯公司 | Ｐｉ３ｋ-德爾塔抑制劑以及其應用和生產方法 |
| EA201490905A1 (ru) | 2011-11-01 | 2014-11-28 | Экселиксис, Инк. | N-(3-{[(3-{[2-хлор-5-(метокси)фенил]амино}хиноксалин-2-ил)амино]сульфонил}фенил)-2-метилаланинамид как ингибитор фосфатидилинозитол-3-киназы для лечения лимфопролиферативных злокачественных заболеваний |
| AU2015283671B2 (en) * | 2014-07-04 | 2018-07-05 | Lupin Limited | Quinolizinone derivatives as Pl3K inhibitors |
| MD3497103T2 (ro) * | 2016-08-15 | 2021-08-31 | Pfizer | Inhibitori de piridopirimidinonă CDK2/4/6 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US7019002B2 (en) | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| WO2007044481A1 (fr) | 2005-10-07 | 2007-04-19 | Basf Corporation | Composition de revetement d’enduit lustre |
| EP1940839B1 (fr) * | 2005-10-07 | 2013-07-31 | Exelixis, Inc. | INHIBITEURS DE PI3Kalpha DE TYPE PYRIDOPYRIMIDINONE |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8101622B2 (en) * | 2008-09-30 | 2012-01-24 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα and mTOR |
| JP5709766B2 (ja) * | 2009-03-12 | 2015-04-30 | ジェネンテック， インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用 |
| AR080151A1 (es) * | 2010-02-09 | 2012-03-14 | Exelixis Inc | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia |
| WO2012065019A2 (fr) * | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Inhibiteurs pyridopyrimidinone de p13k alpha |
-
2012
- 2012-04-27 AR ARP120101507A patent/AR086209A1/es unknown
- 2012-04-27 CN CN201280031493.4A patent/CN103635183A/zh active Pending
- 2012-04-27 MX MX2013012486A patent/MX2013012486A/es unknown
- 2012-04-27 AU AU2012249500A patent/AU2012249500A1/en not_active Abandoned
- 2012-04-27 TW TW101115046A patent/TW201311683A/zh unknown
- 2012-04-27 UY UY0001034044A patent/UY34044A/es not_active Application Discontinuation
- 2012-04-27 JP JP2014508596A patent/JP2014513104A/ja not_active Withdrawn
- 2012-04-27 KR KR1020137031629A patent/KR20140040726A/ko not_active Application Discontinuation
- 2012-04-27 EA EA201391606A patent/EA201391606A1/ru unknown
- 2012-04-27 CA CA2834282A patent/CA2834282A1/fr active Pending
- 2012-04-27 EP EP12720743.9A patent/EP2701690A1/fr not_active Withdrawn
- 2012-04-27 WO PCT/US2012/035442 patent/WO2012149308A1/fr active Application Filing
- 2012-04-27 US US14/114,721 patent/US20140296265A1/en not_active Abandoned
-
2013
- 2013-10-24 ZA ZA2013/07952A patent/ZA201307952B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391606A1 (ru) | 2016-01-29 |
| TW201311683A (zh) | 2013-03-16 |
| JP2014513104A (ja) | 2014-05-29 |
| ZA201307952B (en) | 2014-06-25 |
| UY34044A (es) | 2012-11-30 |
| CA2834282A1 (fr) | 2012-11-01 |
| AR086209A1 (es) | 2013-11-27 |
| AU2012249500A1 (en) | 2013-11-28 |
| WO2012149308A1 (fr) | 2012-11-01 |
| MX2013012486A (es) | 2014-05-28 |
| EP2701690A1 (fr) | 2014-03-05 |
| CN103635183A (zh) | 2014-03-12 |
| US20140296265A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201306842A (zh) | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 | |
| TWI649326B (zh) | 苯并氧氮呯噁唑啶酮化合物及其製備方法 | |
| EP2364302B1 (fr) | Analogues de triazines et leur utilisation en tant qu'agents thérapeutiques et sondes de diagnostic | |
| CN102271681B (zh) | Cxcr7调节剂 | |
| US20220135570A1 (en) | Fused pyrazine derivatives as a2a / a2b inhibitors | |
| JP2021532109A (ja) | イソキノリン化合物及びその使用 | |
| EP3820873B1 (fr) | Agents de dégradation sélectifs des récepteurs des oestrogènes | |
| WO2021113436A1 (fr) | Inhibiteurs de hif-2 alpha | |
| TW200930364A (en) | Organic compounds | |
| JP2021531311A (ja) | ナフチリジン化合物およびその使用 | |
| JP2010523681A (ja) | 癌の治療のためのＰＩ３Ｋ−αの阻害剤としてのピリド［２，３−Ｄ］ピリミジン−７−オン化合物 | |
| JP2021530486A (ja) | 選択的エストロゲン受容体分解剤 | |
| US20200085823A1 (en) | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same | |
| TW202116770A (zh) | 類鐸受體促效劑 | |
| JP2020529418A (ja) | Ｔ細胞急性リンパ芽球性白血病を治療するための化合物、組成及び方法 | |
| KR20140040726A (ko) | PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법 | |
| CN115768769A (zh) | 四氢异喹啉类化合物及其用途 | |
| US20230090742A1 (en) | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors | |
| KR20140077911A (ko) | 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 | |
| EP4274567A1 (fr) | Formes et formulations d'un inhibiteur de la tyrosine kinase non-récepteur 1 (tnk1) | |
| WO2022204720A1 (fr) | Composés de (furopyrimidin-4-yl)pipérazine et leurs utilisations | |
| EA045961B1 (ru) | Селективные супрессоры рецептора эстрогена | |
| JP2022509257A (ja) | ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |